Evidence map›Paper›PMID 41541502›Full record

ArticleJHEP reports : innovation in hepatology2026

Self-supervised learning to predict intrahepatic cholangiocarcinoma transcriptomic classes on routine histology.

Aurélie Beaufrère, Tristan Lazard, Rémy Nicolle, Gwladys Lubuela, Jérémy Augustin, Miguel Albuquerque, Baptiste Pichon, Camille Pignolet, Victoria Priori, Nathalie Théou-Anton and 7 more

Abstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Aurélie BeaufrèreAP-HP.Nord, Department of Pathology, FHU MOSAIC, DMU DREAM, Beaujon Hospital, Clichy, France.
Tristan LazardCenter for Computational Biology (CBIO), Mines Paris, INSERM U900, Institut Curie, PSL University, Paris, France.
Rémy NicolleUniversité Paris Cité, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France.
Gwladys LubuelaUniversité Paris Cité, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France.
Jérémy AugustinAP-HP, Henri Mondor-Albert Chenevier University Hospital, Department of Pathology, Créteil, France.
Miguel AlbuquerqueAP-HP.Nord, Department of Pathology, FHU MOSAIC, DMU DREAM, Beaujon Hospital, Clichy, France.
Baptiste PichonUniversité Paris Cité, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France.
Camille PignoletUniversité Paris Cité, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France.
Victoria PrioriUniversité Paris Cité, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France.
Nathalie Théou-AntonAP-HP.Nord, Department of Molecular Genetics, Bichat Hospital, Paris, France.
Mickael LesurtelAP-HP.Nord, Department of HPB Surgery & Liver Transplantation, Beaujon Hospital, Université Paris Cité, Clichy, France.
Mohamed BouattourUniversité Paris Cité, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France.
Kévin MondetAP-HP.Nord, Department of Pathology, FHU MOSAIC, DMU DREAM, Beaujon Hospital, Clichy, France.
Jérôme CrosAP-HP.Nord, Department of Pathology, FHU MOSAIC, DMU DREAM, Beaujon Hospital, Clichy, France.
Julien CalderaroAP-HP, Henri Mondor-Albert Chenevier University Hospital, Department of Pathology, Créteil, France.
Thomas WalterCenter for Computational Biology (CBIO), Mines Paris, INSERM U900, Institut Curie, PSL University, Paris, France.
Valérie ParadisAP-HP.Nord, Department of Pathology, FHU MOSAIC, DMU DREAM, Beaujon Hospital, Clichy, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: The transcriptomic classification of intrahepatic cholangiocarcinoma (iCCA) has recently been refined from two to five classes, each associated with pathological features, targetable genetic alterations, and survival outcomes. Despite its potential prognostic and therapeutic value, the transcriptomic classification is not routinely used in practice because of technical limitations, including insufficient tissue material and the high cost of molecular analyses. Here, we assessed a self-supervised learning (SSL) model for predicting iCCA transcriptomic classes on digitised whole-slide images (WSIs). Methods: Transcriptomic classes defined from RNA sequencing data were available for all samples. The SSL method (Giga-SSL) was used to train our model on a discovery set of 766 WSIs from 137 biopsies and 109 surgical specimens obtained from 246 patients, using a five-fold cross-validation scheme. The model was validated in The Cancer Genome Atlas (TCGA) cohort (n = 29) and a French external validation set (n = 32), both using WSIs from surgical samples. Results: The most frequent transcriptomic class was the hepatic stem-like class (37% [90/246] in the discovery set). Our model showed good to very good performance in predicting the four most frequent transcriptomic classes in the discovery set (AUC 0.63-0.84), especially for the hepatic stem-like class (AUC 0.84). The model performed equally well in predicting these transcriptomic classes in the two validation sets, with AUCs ranging from 0.76 to 0.80 in the TCGA set and 0.62 to 0.92 in the French external set. Conclusions: We developed and validated an SSL-based model capable of predicting iCCA transcriptomic classes from routine histological slides of both biopsy and surgical samples. This approach may facilitate the clinical implementation of transcriptomic classification, improve prognostic assessment, and guide therapeutic decision-making in iCCA. Impact and implications: Predicting transcriptomic classes directly from routine histological slides has the potential to enhance the clinical management of intrahepatic cholangiocarcinoma, enabling more accurate prognostication and supporting therapeutic decision-making. By eliminating the need for manual slide annotation, large tissue samples, or resource-intensive molecular analyses, our self-supervised learning-based model offers a practical and scalable solution that can be applied to both biopsy and surgical specimens. This approach could accelerate the adoption of transcriptomic classification in everyday practice and help guide more personalized treatment strategies for patients with intrahepatic cholangiocarcinoma.

Indexed as

histological slideintrahepatic cholangiocarcinomaself-supervised learningTranscriptomic classes

Identifiers

PMID41541502
PMCPMC12800354

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.